UMB Bank n.a. Reduces Stock Holdings in Danaher Co. (NYSE:DHR)

UMB Bank n.a. decreased its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 2.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 110,005 shares of the conglomerate's stock after selling 3,090 shares during the period. UMB Bank n.a.'s holdings in Danaher were worth $25,252,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Trueblood Wealth Management LLC boosted its stake in shares of Danaher by 4.4% in the fourth quarter. Trueblood Wealth Management LLC now owns 3,532 shares of the conglomerate's stock valued at $811,000 after purchasing an additional 150 shares during the period. Mechanics Bank Trust Department increased its holdings in shares of Danaher by 14.8% in the 4th quarter. Mechanics Bank Trust Department now owns 9,233 shares of the conglomerate's stock valued at $2,119,000 after acquiring an additional 1,193 shares during the last quarter. Diversify Wealth Management LLC lifted its position in shares of Danaher by 7.8% in the 4th quarter. Diversify Wealth Management LLC now owns 8,186 shares of the conglomerate's stock worth $1,924,000 after buying an additional 592 shares during the last quarter. Hall Laurie J Trustee boosted its stake in Danaher by 5.2% in the fourth quarter. Hall Laurie J Trustee now owns 21,669 shares of the conglomerate's stock valued at $4,974,000 after acquiring an additional 1,065 shares during the period. Finally, Ballast Inc. grew its stake in Danaher by 4.9% during the 4th quarter. Ballast Inc. now owns 5,250 shares of the conglomerate's stock worth $1,205,000 after buying an additional 245 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Stock Down 1.4 %

Shares of NYSE DHR traded down $3.49 during trading on Monday, hitting $238.41. The stock had a trading volume of 3,044,734 shares, compared to its average volume of 2,640,177. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market capitalization of $172.20 billion, a PE ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. Danaher Co. has a 12 month low of $222.53 and a 12 month high of $281.70. The firm has a fifty day moving average of $234.85 and a two-hundred day moving average of $253.51.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher's revenue for the quarter was up 3.1% on a year-over-year basis. During the same period last year, the firm earned $2.02 EPS. As a group, equities research analysts forecast that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher's dividend payout ratio (DPR) is currently 20.61%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on DHR shares. TD Cowen increased their price target on Danaher from $310.00 to $315.00 and gave the stock a "buy" rating in a research note on Wednesday, October 23rd. Evercore ISI upped their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. Bank of America upgraded shares of Danaher from a "neutral" rating to a "buy" rating and set a $290.00 price target for the company in a report on Friday, December 13th. Robert W. Baird reduced their target price on shares of Danaher from $278.00 to $277.00 and set an "outperform" rating for the company in a research note on Wednesday, October 23rd. Finally, Guggenheim started coverage on Danaher in a report on Thursday, December 19th. They issued a "buy" rating and a $275.00 target price for the company. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.